Ann: Export and Import Approvals for Clinical Studies Received, page-10

Indeed refresher, and their appetite for small biotechs progressing clinical trials for anti acne products is growing fast, can't blame 'em with statistics showing that about 80% of people between the ages of 11 and 30 are affected by acne, and in some cases, acne persisting into middle age and beyond. According to World Health Organization, skin conditions can reduce quality of life, affecting physical, mental, and social capabilities. Research also implies that about 50% of women have faced adult acne and that the number of adult sufferers is on the rise.

Here's a breakdown of BioPharmX, they're doing A phase2 study (see my previous post circa projected sales for their BPX01):



Top Institutional Holders

	Holder	Shares	Date Reported	% Out	Value
1	Vivo Capital, LLC	12,814,286	‎Dec‎ ‎31‎, ‎2016	18.92%	4,792,542
2	Franklin Resources, Inc	9,499,615	‎Dec‎ ‎31‎, ‎2016	14.03%	3,552,856
3	EcoR1 Capital, LLC	1,342,000	‎Dec‎ ‎31‎, ‎2016	1.98%	501,908
4	RTW Investments LP	1,273,128	‎Dec‎ ‎31‎, ‎2016	1.88%	476,149
5	Sio Capital Management, LLC	1,143,400	‎Dec‎ ‎31‎, ‎2016	1.69%	427,631
6	Sabby Management, LLC	708,046	‎Dec‎ ‎31‎, ‎2016	1.05%	264,809
7	Vanguard Group, Inc. (The)	264,885	‎Dec‎ ‎31‎, ‎2016	0.39%	99,066
8	PanAgora Asset Management, Inc.	80,735	‎Dec‎ ‎31‎, ‎2016	0.12%	30,194
9	DAFNA Capital Management, LLC	77,031	‎Dec‎ ‎31‎, ‎2016	0.11%	28,809
10	LPL Financial Corporation	40,000	‎Dec‎ ‎31‎, ‎2016	0.06%	14,960

Top Mutual Fund Holders

	Holder	Shares	Date Reported	% Out	Value
1	Franklin Strategic Series-Franklin Biotechnology Discove	216,000	‎Jul‎ ‎31‎, ‎2016	0.32%	155,520
2	Vanguard Total Stock Market Index Fund	144,070	‎Sep‎ ‎30‎, ‎2016	0.21%	79,958
3	Claymore ETF Tr-Wilshire Micro Cap ETF	5,483	‎Nov‎ ‎30‎, ‎2016	0.01%	1,699